NeoGenomics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NeoGenomics and other ETFs, options, and stocks.

About NEO

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. 

CEO
Anthony P. Zook
CEOAnthony P. Zook
Employees
2,500
Employees2,500
Headquarters
Fort Myers, Florida
HeadquartersFort Myers, Florida
Founded
1998
Founded1998
Employees
2,500
Employees2,500

NEO Key Statistics

Market cap
1.85B
Market cap1.85B
Price-Earnings ratio
-18.42
Price-Earnings ratio-18.42
Dividend yield
Dividend yield
Average volume
3.78M
Average volume3.78M
High today
$14.59
High today$14.59
Low today
$13.82
Low today$13.82
Open price
$14.34
Open price$14.34
Volume
2.60M
Volume2.60M
52 Week high
$15.57
52 Week high$15.57
52 Week low
$4.72
52 Week low$4.72

Stock Snapshot

NeoGenomics(NEO) stock is priced at $14.24, giving the company a market capitalization of 1.85B. It carries a P/E multiple of -18.42.

On 2026-07-09, NeoGenomics(NEO) stock moved within a range of $13.82 to $14.59. With shares now at $14.24, the stock is trading +3.1% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 2.6M, compared to an average daily volume of 3.78M.

The stock's 52-week range extends from a low of $4.72 to a high of $15.57.

The stock's 52-week range extends from a low of $4.72 to a high of $15.57.

NEO News

Investing.com 3d
Neogenomics stock hits 52-week high at 15.56 USD - Investing.com

...

Neogenomics stock hits 52-week high at 15.56 USD - Investing.com
Simply Wall St 7d
Is NeoGenomics Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?

In June 2026, NeoGenomics, Inc. announced it had appointed Carolyn Starrett, former Flatiron Health CEO and experienced healthcare data and AI leader, to its Bo...

Is NeoGenomics Quietly Reframing Its Oncology Data Strategy With Starrett’s Board Appointment?

Analyst ratings

67%

of 12 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own NEO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.